0.7767
전일 마감가:
$0.704
열려 있는:
$0.7018
하루 거래량:
1.68M
Relative Volume:
0.54
시가총액:
$93.17M
수익:
-
순이익/손실:
$-225.14M
주가수익비율:
-0.3963
EPS:
-1.96
순현금흐름:
$-192.27M
1주 성능:
+20.21%
1개월 성능:
+64.80%
6개월 성능:
+2.86%
1년 성능:
-68.30%
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
1601 TRAPELO ROAD, WALTHAM
IVVD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IVVD
Invivyd Inc
|
0.7767 | 77.51M | 0 | -225.14M | -192.27M | -1.96 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2023-05-01 | 개시 | H.C. Wainwright | Buy |
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | I - GuruFocus
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript - Insider Monkey
Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns - Investing.com Nigeria
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss - Investing.com Canada
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss By Investing.com - Investing.com South Africa
Invivyd Reports Q1 2025 Financial Results and Outlook - TipRanks
Invivyd’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, A - Barchart.com
Transcript : Invivyd, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strate - GuruFocus
Invivyd Reports Q1 2025 Financial Results and Highlights - TipRanks
INVIVYD Earnings Results: $IVVD Reports Quarterly Earnings - Nasdaq
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines By Investing.com - Investing.com South Africa
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ - MSN
What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings - Yahoo Finance
Invivyd (IVVD) Urges FDA to Revise COVID-19 Vaccine Development - GuruFocus
Invivyd Urges US FDA to Focus on Monoclonal Antibodies for COVID-19 Prevention, Re-Assess Vaccine Efficacy - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines - Investing.com Australia
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy - The Manila Times
Invivyd Urges FDA to Revolutionize COVID-19 Prevention: Calls for Major Shift from Vaccines to Antibody Treatments - Stock Titan
INVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Invivyd initiates measles monoclonal antibody discovery program - BioWorld MedTech
What Does Invivyd Inc’s (NASDAQ: IVVD) Future Hold? - Stocksregister
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Yahoo Finance
Invivyd (IVVD) Advances Measles Monoclonal Antibody Program | IV - GuruFocus
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ By Stocktwits - Investing.com India
Invivyd begins discovery of measles monoclonal antibody By Investing.com - Investing.com South Africa
Invivyd Launches Program for Measles Antibody Treatment - TipRanks
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles - The Manila Times
Invivyd begins discovery of measles monoclonal antibody - Investing.com
Invivyd Announces New Pipeline Discovery Program - marketscreener.com
INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, ADGI - Barchart.com
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - The Manila Times
Invivyd, Inc. to Host Conference Call on May 15, 2025, to Discuss Q1 Financial Results and Business Highlights - Nasdaq
Senior Manager, Marketing Operations Waltham/Bostonwill consider remote at Invivyd, Inc. - Mediabistro
Invivyd Inc (NASDAQ: IVVD): Should Value Hunters Buy It? - Stocksregister
Geode Capital Management LLC Has $708,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - The AM Reporter
Invivyd Inc (IVVD) expanding its growth trajectory ahead - Sete News
Guggenheim Upgrades Invivyd Inc (IVVD) to a Buy from a Neutral - knoxdaily.com
Market Recap Check: Invivyd Inc (IVVD)’s Negative Finish at 0.64, Up/Down -3.97 - DWinneX
Will Invivyd Inc (IVVD) meet earnings estimates this quarter? - uspostnews.com
What is Invivyd Inc (IVVD) Stock Return on Shareholders’ Capital? - Sete News
Guggenheim upgrades Invivyd Inc (IVVD) rating to a Buy - knoxdaily.com
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd (IVVD) Secures $30M Loan Facility from Silicon Valley Ba - GuruFocus
Invivyd Inc (IVVD) Stock: A Comprehensive 52-Week Review - investchronicle.com
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Invivyd Inc 주식 (IVVD) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
자본화:
|
볼륨(24시간):